Vanda Pharmaceuticals Celebrates FDA Acceptance for Imsidolimab in GPP Treatment Vanda Pharmaceuticals announces that the FDA has accepted its filing for Imsidolimab to treat Generalized Pustular Psoriasis. A potential breakthrough in dermatological therapies.

Vanda Pharmaceuticals Celebrates FDA Acceptance for Imsidolimab in GPP Treatment #USA #Washington #Vanda_Pharmaceuticals #Imsidolimab #Generalized_Pustular_Psoriasis